Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 28.48 · gapped below the open, then crossed back over prior close. High/low 28.58 at 3:15 pm ET, 25.76 at 4:00 am ET.
Caris Life Sciences, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Services-Medical Laboratories
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In July 2024, we entered into a master supply agreement with Roche Diagnostics Corporation ("Roche"), for Roche to provide sequencing probes and other testing supplies and equipment for clinical and research uses in our laboratory operations (the "Roche Agreement").”
FILING10-K0002019410-26-000016cik 0002019410
“Through an exclusive license arrangement with Washington University in St. Louis ("WashU") that we entered into in October 2024, we are developing Caris ChromoSeq, an assay that detects and analyzes hematological cancers using WGS and WTS.”
FILING10-K0002019410-26-000016cik 0002019410
“We currently host our data on, and conduct certain data analysis through, Amazon Web Services ("AWS") cloud-based hosting facilities as well as on our own co-located or on-premise computing infrastructure.”
FILING10-K0002019410-26-000016cik 0002019410
“We rely on Illumina, Inc. ("Illumina") as the sole supplier of NGS instruments and the associated sequencing reagent kits for our solutions.”
FILING10-K0002019410-26-000016cik 0002019410
“The test was developed using tumor specimens and clinical data from the TAILORx (ECOG) and B-42 (NRG) randomized clinical trials.”
FILING10-K0002019410-26-000016cik 0002019410
“The test was developed using tumor specimens and clinical data from the TAILORx (ECOG) and B-42 (NRG) randomized clinical trials.”
FILING10-K0002019410-26-000016cik 0002019410
“For example, the February 2024 cybersecurity attack on Change Healthcare, who we used to process certain insurance claims, resulted in a delay in our ability to submit claims for payment and could require us to issue notifications to impacted individuals and various regulators if Change Healthcare determines that any PHI of our patients was impacted.”
FILING10-K0002019410-26-000016cik 0002019410
“Both of our Phoenix laboratories hold CAP accreditations upon which our CLIA Certificate of Accreditation are based.”
FILING10-K0002019410-26-000016cik 0002019410
“To further broaden the applicability and usefulness of our multi-modal datasets for biopharma companies, we have entered into agreements with clinical data partners, such as ConcertAI, Flatiron and COTA, to enable the creation of matched clinico-genomic datasets that can be licensed to biopharma companies for their use in drug discovery.”
FILING10-K0002019410-26-000016cik 0002019410
“To further broaden the applicability and usefulness of our multi-modal datasets for biopharma companies, we have entered into agreements with clinical data partners, such as ConcertAI, Flatiron and COTA, to enable the creation of matched clinico-genomic datasets that can be licensed to biopharma companies for their use in drug discovery.”
FILING10-K0002019410-26-000016cik 0002019410
“To further broaden the applicability and usefulness of our multi-modal datasets for biopharma companies, we have entered into agreements with clinical data partners, such as ConcertAI, Flatiron and COTA, to enable the creation of matched clinico-genomic datasets that can be licensed to biopharma companies for their use in drug discovery.”
FILING10-K0002019410-26-000016cik 0002019410
“Our molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.”
FILING10-K0002019410-26-000016cik 0002019410
“Our molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.”
FILING10-K0002019410-26-000016cik 0002019410
“Our molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.”
FILING10-K0002019410-26-000016cik 0002019410
“Our molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.”
FILING10-K0002019410-26-000016cik 0002019410
“We have obtained Medicare coverage under the NGS NCD for MI Cancer Seek for CPT code 0211U.”
FILING10-K0002019410-26-000016cik 0002019410
“Our molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.”
FILING10-K0002019410-26-000016cik 0002019410
“We have entered into a collaboration agreement with Everlywell to expand access to Caris Detect.”
FILING10-K0002019410-26-000016cik 0002019410
Watchlist prices, news filtered to it, and its next report on your desk.
Caris Life Sciences, Inc. has 11 disclosed suppliers and 7 disclosed customers. Each one is named in an SEC filing, either Caris Life Sciences, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
CAI (Caris Life Sciences, Inc.) has 11 disclosed suppliers and 7 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ILMN +7.58%, in healthcare.